MCID: ERY003
MIFTS: 62

Erythema Multiforme

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Erythema Multiforme

MalaCards integrated aliases for Erythema Multiforme:

Name: Erythema Multiforme 12 77 54 38 56 45 15 17 74
Erythema Polymorphe, Erythema Multiforme Type 54
Dermatostomatitis, Erythema Multiforme Type 54
Herpes Iris, Erythema Multiforme Type 54
Febrile Mucocutaneous Syndrome 54
Erythema Multiforme Bullosum 54
Stevens-Johnson Syndrome 74
Em 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050185
KEGG 38 H01695
MeSH 45 D004892
ICD10 34 L51

Summaries for Erythema Multiforme

NIH Rare Diseases : 54 Erythema multiforme (EM) refers to a group of hypersensitivity disorders characterized by symmetric red, patchy lesions, primarily on the arms and legs. The cause is unknown, but EM frequently occurs in association with herpes simplex virus, suggesting an immunologic process initiated by the virus. In half of the cases, the triggering agents appear to be medications, including anticonvulsants, sulfonamides, nonsteroidal anti-inflammatory drugs, and other antibiotics. In addition, some cases appear to be associated with infectious organisms such as Mycoplasma pneumoniae and many viral agents. Erythema multiforme is the mildest of three skin disorders that are often discussed in relation to each other. It is generally the mildest of the three. More severe is Stevens-Johnson syndrome. The most severe of the three is toxic epidermal necrolysis (TEN).

MalaCards based summary : Erythema Multiforme, also known as erythema polymorphe, erythema multiforme type, is related to severe cutaneous adverse reaction and pulmonary fibrosis, idiopathic. An important gene associated with Erythema Multiforme is DSP (Desmoplakin), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs Sirolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and prostate, and related phenotypes are Decreased hepcidin::fluc mRNA expression and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A skin disease that is a type of allergic reaction located in skin, which occurs in response to medications, infections, or illness.

Wikipedia : 77 Erythema multiforme (EM) is a skin condition of unknown cause; it is a type of erythema possibly... more...

Related Diseases for Erythema Multiforme

Diseases related to Erythema Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 445, show less)
# Related Disease Score Top Affiliating Genes
1 severe cutaneous adverse reaction 31.7 FASLG GZMB HSPG2 TNF
2 pulmonary fibrosis, idiopathic 31.2 CCL17 CXCR3 DSP FASLG IFNG TNF
3 fixed drug eruption 30.7 IFNG IL2
4 contact dermatitis 30.5 CCL17 CXCR3 ICAM1 IFNG TNF
5 colitis 30.5 IFNG IL2 TNF
6 variola major 30.5 IFNG IL2
7 human immunodeficiency virus infectious disease 30.4 IFNG IL2 TNF
8 chronic graft versus host disease 30.4 IFNG TNF
9 ulcerative colitis 30.4 IFNG IL2 TNF
10 stevens-johnson syndrome/toxic epidermal necrolysis 30.4 CCL17 CXCR3 IFNG IL2
11 leprosy 3 30.4 IFNG IL2 TNF
12 smallpox 30.2 IFNG IL2 TNF
13 annular erythema 30.2 HSPG2 ICAM1
14 myocarditis 30.1 DSP ICAM1 TNF
15 autoimmune disease 30.0 IFNG IL2 TNF
16 allergic contact dermatitis 30.0 CCL17 CXCR3 ICAM1 IFNG TNF
17 hematopoietic stem cell transplantation 30.0 IFNG IL2 TNF
18 conjunctivitis 30.0 ICAM1 IFNG IL2
19 mumps 30.0 IFNG IL2 TNF
20 poliomyelitis 30.0 ICAM1 IFNG TNF
21 exanthem 29.9 HSPG2 IL2 TNF
22 lymphopenia 29.9 FASLG IFNG IL2
23 orofacial granulomatosis 29.8 CXCR3 IFNG TNF
24 graft-versus-host disease 29.8 FASLG GZMB IFNG IL2 TNF
25 hemophagocytic lymphohistiocytosis 29.7 GZMB IFNG TNF
26 lichen planus 29.6 CXCR3 GZMB ICAM1 IFNG TNF
27 cutaneous lupus erythematosus 29.6 CXCR3 GZMB ICAM1 TNF
28 keratoconjunctivitis 29.6 CCL17 ICAM1 IFNG IL2 TNF
29 rheumatoid arthritis 29.6 ICAM1 IFNG IL2 TNF
30 mycosis fungoides 29.6 CCL17 CXCR3 GZMB IL2
31 trypanosomiasis 29.4 ICAM1 IFNG IL2 TNF
32 acute graft versus host disease 29.4 FASLG GZMB IFNG IL2 TNF
33 systemic lupus erythematosus 29.4 CXCR3 FASLG ICAM1 IFNG IL2 TNF
34 dermatitis, atopic 29.4 CCL17 ICAM1 IFNG IL2 TNF
35 lymphadenitis 29.2 CXCR3 FASLG ICAM1 IFNG TNF
36 multiple sclerosis 29.0 CXCR3 ICAM1 IFNG IL2 TNF
37 alopecia areata 28.9 FASLG GZMB ICAM1 IFNG IL2 TNF
38 malaria 28.7 CXCR3 FASLG ICAM1 IFNG IL2 TNF
39 erythema multiforme major 12.6
40 eosinophilia-myalgia syndrome 12.3
41 epileptic encephalopathy, early infantile, 3 11.4
42 epileptic encephalopathy, early infantile, 4 11.4
43 erythromelalgia 11.3
44 pseudomembranous conjunctivitis 11.2
45 pulmonary embolism 11.2
46 encephalopathy, ethylmalonic 11.1
47 alpha-1-antitrypsin deficiency 11.1
48 x-linked intellectual disability-macrocephaly-macroorchidism syndrome 10.9
49 dermatitis 10.8
50 herpes simplex 10.8
51 lupus erythematosus 10.6
52 keratolytic winter erythema 10.6
53 cardiac arrest 10.5
54 hepatitis 10.5
55 pneumonia 10.4
56 pemphigus 10.4
57 oral tuberculosis 10.4 IL2 TNF
58 streptococcal toxic-shock syndrome 10.4 IL2 TNF
59 lymphoma 10.4
60 toxicodendron dermatitis 10.3 ICAM1 IL2
61 farmer's lung 10.3 IL2 TNF
62 dermatitis herpetiformis, familial 10.3
63 hepatitis b 10.3
64 dermatitis herpetiformis 10.3
65 shwartzman phenomenon 10.3 ICAM1 TNF
66 autoimmune gastritis 10.3 IL2 TNF
67 actinic prurigo 10.3 ICAM1 TNF
68 burning mouth syndrome 10.3 IL2 TNF
69 arthritis 10.3
70 syphilis 10.3
71 bullous pemphigoid 10.3
72 staphylococcal toxic shock syndrome 10.3 IFNG TNF
73 rheumatoid vasculitis 10.3 ICAM1 TNF
74 autoimmune myocarditis 10.3 IFNG TNF
75 arthus reaction 10.3 ICAM1 TNF
76 trichosporonosis 10.3 IFNG TNF
77 chronic beryllium disease 10.3 IFNG TNF
78 herpes zoster 10.3
79 scleritis 10.3 IFNG TNF
80 berylliosis 10.3 IFNG IL2
81 miliary tuberculosis 10.3 IFNG TNF
82 atopic keratoconjunctivitis 10.2 IFNG IL2
83 microscopic colitis 10.2 IFNG TNF
84 lymphangiosarcoma 10.2 DSP IL2 TNF
85 meconium aspiration syndrome 10.2 IFNG TNF
86 central nervous system vasculitis 10.2 IFNG TNF
87 lung cancer 10.2
88 urticaria 10.2
89 histoplasmosis 10.2
90 secondary syphilis 10.2
91 psoriasis 10.2
92 cytomegalovirus infection 10.2
93 hypersensitivity reaction type iii disease 10.2 ICAM1 TNF
94 soft tissue sarcoma 10.2 IFNG TNF
95 tuberculous peritonitis 10.2 IFNG TNF
96 chronic active epstein-barr virus infection 10.2 IFNG IL2
97 primary systemic mycosis 10.2 IFNG TNF
98 renal cell carcinoma, nonpapillary 10.2
99 leukemia 10.2
100 hepatitis c 10.2
101 cytomegalovirus retinitis 10.2 IFNG TNF
102 paragonimiasis 10.2 CCL17 CXCR3
103 mycoplasma pneumoniae pneumonia 10.2 IFNG TNF
104 chronic eosinophilic pneumonia 10.2 CXCR3 ICAM1
105 breast medullary carcinoma 10.1 FASLG GZMB
106 sialadenitis 10.1 HSPG2 TNF
107 alveolar echinococcosis 10.1 CCL17 TNF
108 medial medullary syndrome 10.1
109 clonorchiasis 10.1 IFNG IL2 TNF
110 crohn's colitis 10.1 IFNG IL2 TNF
111 lymphocytic gastritis 10.1 FASLG GZMB
112 posterior uveitis 10.1 IFNG IL2 TNF
113 coccidiosis 10.1 IFNG IL2 TNF
114 hypersensitivity reaction type iv disease 10.1 IFNG IL2 TNF
115 vernal keratoconjunctivitis 10.1 CXCR3 ICAM1
116 eales disease 10.1 IFNG TNF
117 paracoccidioidomycosis 10.1 IFNG IL2 TNF
118 testicular disease 10.1 IFNG IL2 TNF
119 autoimmune glomerulonephritis 10.1 GZMB ICAM1
120 brucellosis 10.1 IFNG IL2 TNF
121 peanut allergy 10.1 CCL17 IFNG
122 tonsillitis 10.1 IFNG IL2 TNF
123 filariasis 10.1 IFNG IL2 TNF
124 primary bacterial infectious disease 10.1 IFNG IL2 TNF
125 plasmodium vivax malaria 10.1 ICAM1 IFNG TNF
126 visceral leishmaniasis 10.1 IFNG IL2 TNF
127 bone inflammation disease 10.1 IFNG IL2 TNF
128 toxic shock syndrome 10.1 IFNG IL2 TNF
129 schistosomiasis 10.1 IFNG IL2 TNF
130 lymphomatoid papulosis 10.1 FASLG GZMB
131 pfeiffer syndrome 10.1
132 pemphigus vulgaris, familial 10.1
133 kawasaki disease 10.1
134 pemphigus vulgaris 10.1
135 tetanus 10.1
136 diphtheria 10.1
137 melanoma 10.1
138 genital herpes 10.1
139 pityriasis rosea 10.1
140 dermatophytosis 10.1
141 stomatitis 10.1
142 hypereosinophilic syndrome 10.1
143 autoimmune progesterone dermatitis 10.1
144 hansen's disease 10.1
145 linear iga disease 10.1
146 acquired immunodeficiency syndrome 10.1 IFNG IL2 TNF
147 choriocarcinoma of the testis 10.1 FASLG GZMB
148 chagas disease 10.1 IFNG IL2 TNF
149 pulmonary tuberculosis 10.1 IFNG IL2 TNF
150 upper respiratory tract disease 10.1 ICAM1 IFNG TNF
151 myasthenia gravis 10.1 IFNG IL2 TNF
152 autoimmune disease of endocrine system 10.1 ICAM1 IFNG IL2
153 acute necrotizing encephalitis 10.1 GZMB IFNG
154 immune system disease 10.1 IFNG IL2 TNF
155 plasmodium falciparum malaria 10.1 ICAM1 IFNG TNF
156 relapsing-remitting multiple sclerosis 10.1 ICAM1 IFNG TNF
157 proteasome-associated autoinflammatory syndrome 1 10.1 ICAM1 IFNG TNF
158 gastrointestinal system disease 10.1 IFNG IL2 TNF
159 demyelinating disease 10.1 ICAM1 IFNG TNF
160 viral infectious disease 10.1 IFNG IL2 TNF
161 pleural tuberculosis 10.1 IFNG TNF
162 echinococcosis 10.1 CCL17 IFNG TNF
163 aspergillosis 10.1 CCL17 IFNG TNF
164 oligoarticular juvenile idiopathic arthritis 10.1 CXCR3 TNF
165 common variable immunodeficiency 10.1 IFNG IL2 TNF
166 spotted fever 10.1 IFNG TNF
167 interstitial lung disease 10.0 CCL17 IFNG TNF
168 graves' disease 10.0 FASLG ICAM1 IFNG
169 inflammatory bowel disease 10.0 IFNG IL2 TNF
170 leukemia, chronic lymphocytic 2 10.0
171 breast cancer 10.0
172 leukemia, chronic lymphocytic 10.0
173 small cell cancer of the lung 10.0
174 crohn's disease 10.0
175 granuloma annulare 10.0
176 neutropenia 10.0
177 chlamydia pneumonia 10.0
178 lymphocytic leukemia 10.0
179 legionellosis 10.0
180 pertussis 10.0
181 rabies 10.0
182 chlamydia 10.0
183 cicatricial pemphigoid 10.0
184 lyme disease 10.0
185 mouth disease 10.0
186 measles 10.0
187 vasculitis 10.0
188 rubella 10.0
189 molluscum contagiosum 10.0
190 cutaneous larva migrans 10.0
191 drug reaction with eosinophilia and systemic symptoms 10.0
192 kikuchi disease 10.0
193 leukemia, b-cell, chronic 10.0
194 subacute cutaneous lupus erythematosus 10.0
195 stevens-johnson syndrome/toxic epidermal necrolysis overlap syndrome 10.0
196 nonspecific interstitial pneumonia 10.0 CXCR3 IFNG
197 mixed connective tissue disease 10.0 HSPG2 IFNG TNF
198 t-cell large granular lymphocyte leukemia 10.0 FASLG GZMB IL2
199 tropical spastic paraparesis 10.0 CXCR3 IFNG IL2
200 influenza 10.0
201 spondyloenchondrodysplasia 10.0
202 b-cell expansion with nfkb and t-cell anergy 10.0 FASLG GZMB IL2
203 mycobacterium tuberculosis 1 10.0 CXCR3 IFNG TNF
204 pustulosis palmaris et plantaris 10.0 CXCR3 TNF
205 nervous system disease 10.0 CXCR3 IFNG TNF
206 central nervous system disease 10.0 CXCR3 IFNG TNF
207 rasmussen encephalitis 10.0 GZMB IFNG TNF
208 aseptic meningitis 10.0 IFNG TNF
209 lepromatous leprosy 9.9 ICAM1 IFNG IL2 TNF
210 autoimmune uveitis 9.9 ICAM1 IFNG IL2 TNF
211 pleurisy 9.9 ICAM1 IFNG IL2 TNF
212 parasitic protozoa infectious disease 9.9 ICAM1 IFNG IL2 TNF
213 respiratory system disease 9.9 ICAM1 IFNG IL2 TNF
214 prostate cancer 9.9
215 helicobacter pylori infection 9.9
216 asthma 9.9
217 prostate cancer, hereditary, 8 9.9
218 ventricular fibrillation, paroxysmal familial, 1 9.9
219 anxiety 9.9
220 prostate cancer, hereditary, 6 9.9
221 dengue virus 9.9
222 blood group, gerbich system 9.9
223 helix syndrome 9.9
224 brain injury 9.9
225 diabetes mellitus 9.9
226 traumatic brain injury 9.9
227 patulous eustachian tube 9.9
228 diarrhea 9.9
229 bipolar i disorder 9.9
230 amyloidosis 9.9
231 depression 9.9
232 progressive multifocal leukoencephalopathy 9.9 IL2 TNF
233 aplastic anemia 9.9 FASLG IFNG IL2 TNF
234 large intestine cancer 9.9 FASLG IFNG IL2 TNF
235 peripheral t-cell lymphoma 9.9 CXCR3 GZMB IL2
236 blood group--ul system 9.9
237 cryoglobulinemia, familial mixed 9.9
238 major affective disorder 1 9.9
239 ocular cicatricial pemphigoid 9.9
240 porphyria cutanea tarda 9.9
241 myeloma, multiple 9.9
242 sjogren syndrome 9.9
243 thymoma, familial 9.9
244 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 9.9
245 myocardial infarction 9.9
246 legionnaire disease 9.9
247 hepatitis c virus 9.9
248 major affective disorder 8 9.9
249 major affective disorder 7 9.9
250 major affective disorder 9 9.9
251 acute promyelocytic leukemia 9.9
252 cholangiocarcinoma 9.9
253 alopecia 9.9
254 autoimmune hepatitis 9.9
255 hemolytic anemia 9.9
256 pemphigus foliaceus 9.9
257 systemic scleroderma 9.9
258 pemphigus gestationis 9.9
259 early congenital syphilis 9.9
260 erythema elevatum diutinum 9.9
261 mucositis 9.9
262 angioimmunoblastic t-cell lymphoma 9.9
263 dermatomyositis 9.9
264 parotitis 9.9
265 legionnaires' disease 9.9
266 henoch-schoenlein purpura 9.9
267 disseminated intravascular coagulation 9.9
268 ornithosis 9.9
269 myopia 9.9
270 nephrotic syndrome 9.9
271 dysentery 9.9
272 entropion 9.9
273 keratoconjunctivitis sicca 9.9
274 tinea unguium 9.9
275 porphyria 9.9
276 pemphigoid gestationis 9.9
277 sporotrichosis 9.9
278 angioedema 9.9
279 giant cell tumor 9.9
280 tularemia 9.9
281 gastroenteritis 9.9
282 relapsing polychondritis 9.9
283 epidermolysis bullosa 9.9
284 cryoglobulinemia 9.9
285 newcastle disease 9.9
286 antiphospholipid syndrome 9.9
287 adenocarcinoma 9.9
288 thymoma 9.9
289 neurodermatitis 9.9
290 purpura 9.9
291 mastocytosis 9.9
292 pancreatitis 9.9
293 reactive arthritis 9.9
294 cutaneous anthrax 9.9
295 anthrax disease 9.9
296 hyperthyroidism 9.9
297 chronic fatigue syndrome 9.9
298 herpetic whitlow 9.9
299 chickenpox 9.9
300 seborrheic dermatitis 9.9
301 ritter's disease 9.9
302 meningitis 9.9
303 polyarteritis nodosa 9.9
304 congenital syphilis 9.9
305 neisseria meningitidis infection 9.9
306 neonatal herpes 9.9
307 perniosis 9.9
308 splenomegaly 9.9
309 t-cell prolymphocytic leukemia 9.9
310 headache 9.9
311 acute generalized exanthematous pustulosis 9.9
312 intermediate uveitis 9.8 CXCR3 IFNG IL2 TNF
313 alzheimer disease 9.8
314 blood group--wright antigen 9.8
315 neutrophil migration 9.8
316 retinoblastoma 9.8
317 moyamoya disease 1 9.8
318 ocular motor apraxia 9.8
319 oculotrichodysplasia 9.8
320 cervical cancer 9.8
321 endometrial cancer 9.8
322 buruli ulcer 9.8
323 intraocular pressure quantitative trait locus 9.8
324 muscle hypertrophy 9.8
325 leptin deficiency or dysfunction 9.8
326 bipolar disorder 9.8
327 gas gangrene 9.8
328 spinal cord injury 9.8
329 chikungunya 9.8
330 osteomyelitis 9.8
331 severe acute respiratory syndrome 9.8
332 substance abuse 9.8
333 early myoclonic encephalopathy 9.8
334 ischemia 9.8
335 cellulitis 9.8
336 erythrasma 9.8
337 endophthalmitis 9.8
338 kidney disease 9.8
339 chorioretinitis 9.8
340 encephalitis 9.8
341 hypoglycemia 9.8
342 al amyloidosis 9.8
343 bowenoid papulosis 9.8
344 cytokine deficiency 9.8
345 degos 'en cocarde' erythrokeratoderma 9.8
346 heparin-induced thrombocytopenia 9.8
347 pain - chronic 9.8
348 syncope 9.8
349 encephalopathy 9.8
350 behcet syndrome 9.8 HSPG2 IFNG IL2 TNF
351 uveitis 9.8 CXCR3 ICAM1 IFNG TNF
352 lichen disease 9.8 CXCR3 ICAM1 IFNG TNF
353 hashimoto thyroiditis 9.8 CXCR3 FASLG ICAM1 IFNG
354 skin disease 9.7 CCL17 DSP ICAM1 IFNG TNF
355 cutaneous t cell lymphoma 9.7 CCL17 GZMB IFNG IL2
356 blood group, colton system 9.7
357 hepatocellular carcinoma 9.7
358 cardiac conduction defect 9.7
359 marfan syndrome 9.7
360 milia, multiple eruptive 9.7
361 motion sickness 9.7
362 carney complex, type 1 9.7
363 pelger-huet anomaly 9.7
364 premature chromatid separation trait 9.7
365 schizophrenia 9.7
366 acrocallosal syndrome 9.7
367 cerebrotendinous xanthomatosis 9.7
368 chondrosarcoma 9.7
369 chordoma 9.7
370 cystic fibrosis 9.7
371 disorganization, mouse, homolog of 9.7
372 epidermodysplasia verruciformis 1 9.7
373 hemochromatosis, type 1 9.7
374 raine syndrome 9.7
375 pulmonary alveolar microlithiasis 9.7
376 testicular regression syndrome 9.7
377 aging 9.7
378 stroke, ischemic 9.7
379 acute insulin response 9.7
380 xanthomatosis 9.7
381 caronte 9.7
382 spondyloocular syndrome 9.7
383 body mass index quantitative trait locus 1 9.7
384 nasopharyngeal carcinoma 9.7
385 headache associated with sexual activity 9.7
386 autoimmune disease 1 9.7
387 tropical calcific pancreatitis 9.7
388 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
389 diabetes mellitus, ketosis-prone 9.7
390 chondrosarcoma, extraskeletal myxoid 9.7
391 gastric cancer 9.7
392 aortic valve disease 2 9.7
393 acute leukemia 9.7
394 acute myocardial infarction 9.7
395 cataract 9.7
396 cerebral hemorrhage 9.7
397 chronic kidney failure 9.7
398 pulmonary fibrosis 9.7
399 spinal muscular atrophy 9.7
400 salivary gland carcinoma 9.7
401 pain agnosia 9.7
402 ischemic colitis 9.7
403 oral hairy leukoplakia 9.7
404 latex allergy 9.7
405 meningococcal meningitis 9.7
406 common cold 9.7
407 eastern equine encephalitis 9.7
408 japanese encephalitis 9.7
409 choreatic disease 9.7
410 dementia 9.7
411 gout 9.7
412 neuroleptic malignant syndrome 9.7
413 cholera 9.7
414 disease of mental health 9.7
415 long qt syndrome 9.7
416 lipid metabolism disorder 9.7
417 fibrosarcoma 9.7
418 clear cell renal cell carcinoma 9.7
419 extraosseous chondrosarcoma 9.7
420 myxoid chondrosarcoma 9.7
421 bronchitis 9.7
422 fibromyalgia 9.7
423 cerebrovascular disease 9.7
424 intestinal obstruction 9.7
425 oropharynx cancer 9.7
426 subacute delirium 9.7
427 learning disability 9.7
428 venezuelan equine encephalitis 9.7
429 xanthogranulomatous cholecystitis 9.7
430 polycystic kidney disease 9.7
431 juvenile hereditary hemochromatosis 9.7
432 rere-related disorders 9.7
433 amyloidosis aa 9.7
434 cervical intraepithelial neoplasia 9.7
435 desmoplastic infantile astrocytoma 9.7
436 gangliosidosis 9.7
437 leukoplakia 9.7
438 proximal spinal muscular atrophy 9.7
439 reversible cerebral vasoconstriction syndrome 9.7
440 ohtahara syndrome 9.7
441 isolated optic neuritis 9.7
442 bronchiolitis obliterans 9.7 CXCR3 GZMB IFNG TNF
443 pulmonary sarcoidosis 9.6 CXCR3 ICAM1 IFNG IL2 TNF
444 autoimmune disease of central nervous system 9.6 CXCR3 ICAM1 IFNG IL2 TNF
445 sarcoidosis 1 9.6 CCL17 CXCR3 IFNG IL2 TNF

Comorbidity relations with Erythema Multiforme via Phenotypic Disease Network (PDN): (showing 3, show less)


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Erythema Multiforme:



Diseases related to Erythema Multiforme

Symptoms & Phenotypes for Erythema Multiforme

GenomeRNAi Phenotypes related to Erythema Multiforme according to GeneCards Suite gene sharing:

27 (showing 3, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased hepcidin::fluc mRNA expression GR00253-A 9.43 ATF3 CCL17 DSP FASLG GZMB HSPG2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.28 GZMB ICAM1 IL2 TNF
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.28 FASLG GZMB ICAM1 IL2 TNF

MGI Mouse Phenotypes related to Erythema Multiforme:

47 (showing 9, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.09 CCL17 CXCR3 DSP FASLG HSPG2 ICAM1
2 cardiovascular system MP:0005385 10.06 CXCR3 DSP FASLG HSPG2 ICAM1 IFNG
3 hematopoietic system MP:0005397 10.02 ATF3 CCL17 CXCR3 FASLG HSPG2 ICAM1
4 immune system MP:0005387 9.97 ATF3 CCL17 CXCR3 FASLG HSPG2 ICAM1
5 digestive/alimentary MP:0005381 9.95 DSP FASLG HSPG2 ICAM1 IFNG IL2
6 integument MP:0010771 9.8 ATF3 DSP FASLG HSPG2 ICAM1 IFNG
7 neoplasm MP:0002006 9.7 ATF3 CXCR3 FASLG ICAM1 IFNG IL2
8 respiratory system MP:0005388 9.5 ATF3 CXCR3 FASLG HSPG2 IFNG IL2
9 vision/eye MP:0005391 9.1 FASLG HSPG2 ICAM1 IFNG IL2 TNF

Drugs & Therapeutics for Erythema Multiforme

Drugs for Erythema Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 887, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 5284616 6436030
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
4
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
5
Cilostazol Approved, Investigational Phase 4,Not Applicable 73963-72-1 2754
6
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 70789204 6442177
7
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
8
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 169590-42-5 2662
9
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33069-62-4 36314
10
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-48-4 104729
11
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
12
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
13
Benzoyl peroxide Approved Phase 4,Phase 3 94-36-0 7187
14
Coal tar Approved Phase 4,Phase 3,Phase 2,Phase 1 8007-45-2
15
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15663-27-1 2767 441203 84093
16
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
17
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
18
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
19
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
20
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
21
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1 73590-58-6 4594
22
Pantoprazole Approved Phase 4 102625-70-7 4679
23 Nutmeg Approved Phase 4,Phase 3,Phase 1,Not Applicable
24
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
25
Tirofiban Approved Phase 4,Not Applicable 144494-65-5 60947
26
Abciximab Approved Phase 4,Phase 2,Phase 3 143653-53-6
27
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 134523-00-5 60823
28
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
29
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
30
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
31
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
32
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
33
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
34
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 46507594 772
35
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 557795-19-4, 341031-54-7 5329102
36
Desonide Approved, Investigational Phase 4,Phase 3 638-94-8 5311066
37
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 154361-50-9 60953
38
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
39
Lenvatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 417716-92-8
40
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
41
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
42
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
43
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
44
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 302-25-0
45
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
46
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2 2921-57-5
47
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
48
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
49
Clobetasol Approved, Experimental, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 25122-46-7, 25122-41-2 5311051 32798
50
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 378-44-9 9782
51
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3 69-72-7 338
52
Pimecrolimus Approved, Investigational Phase 4,Phase 3 137071-32-0 17753757 6447131
53
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
54
Ezetimibe Approved Phase 4 163222-33-1 150311
55
Probucol Approved, Investigational Phase 4 23288-49-5 4912
56
afatinib Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 850140-72-6, 439081-18-2 10184653
57
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 439-14-5 3016
58
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 71486-22-1 44424639 60780
59
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
60
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
61
Zoledronic Acid Approved Phase 4,Phase 2 118072-93-8 68740
62
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 180288-69-1 9903
63
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
64
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Not Applicable 274693-27-5 9871419
65
Polyestradiol phosphate Approved Phase 4,Phase 2,Not Applicable 28014-46-2
66
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 50-28-2 5757